Genomic medicine and neuroblastoma

Expert Review of Molecular Diagnostics

Volumn 3, Issue 1, 2003, Pages 39-54

  Oppenheimer, Orit ^a   Alaminos, Miguel ^a   Gerald, William L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diagnosis; Genetics; Molecular biology; Neuroblastoma; Review

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIPODOPHYLLOTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; ISOTRETINOIN; MOLECULAR MARKER; NEUROTROPHIN; PROTEIN; RNA; TELOMERASE; TYROSINE KINASE RECEPTOR;

AGE; BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CHILDHOOD CANCER; CHROMOSOME 1; DISEASE COURSE; FIBROSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOSS; GENE TECHNOLOGY; GENETIC DISORDER; GENOMICS; HISTOPATHOLOGY; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; NEURAL CREST; NEUROBLASTOMA; PATHOGENESIS; PLOIDY; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SOLID TUMOR; TUMOR CALCINOSIS;

CHROMOSOME ABERRATIONS; GENETIC TECHNIQUES; HUMANS; MUTATION; NEUROBLASTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 12244277028     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.1.39     Document Type: Review

References (207)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatr Oncology (4th Ed.) Pizzo PA, Poplack DG (Eds). Lippincott, Williams and Wilkens, PA, USA. 894-937 (2002). Excellent review of the standard treatment regimes and diagnostics.
2. Brodeur MB, Clinical and Biological Aspects of Neuroblastoma. In: The Genetic Basis of human Cancer, (2nd Ed.) Vogelstein B, Kinzler KW, NY, USA, 751-772 (2002). Excellent comprehensive review of genetics, biology and clinical aspects of neuroblastoma, including a very good source of references.
3. Voute PA. Neuroblastoma In: Clinical Pediatric Oncology Sutow WW, Fernback DJ, Vietti TJ (Eds). MI, USA 559 (1984).
4. Sawada T, Sugimoto T, Tanaka T et al. Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: future reports. Med. Pediatr. Oncol. 15, 14 (1987).
5. Kinney H, Faix R, Brany J. The fetal alcohol syndrome and neuroblastoma. Pediatrics 66, 130-132 (1999).
6. Schwartzbaum JA. Influence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. Am. J. Epidemiol. 135, 1358-1367 (1992).
7. Kramer S, Ward E, Meadows AT, Malone KE. Medical and Drug risk factors associated with neuroblastoma: a case control study. J. Natl Cancer Inst. 78, 797-804 (1987).
8. Michalek AM, Buck GM, Nasca PC, Freedman AN, Baptiste MS, Mahoney MC, Gravid health status, medication use and risk of neuroblastoma. Am J. Epidemiol. 143, 996-1001 (1996).
9. De Ross AJ, Olshan AF, Teschke K et al. Parental occupation exposures to chemical and incidence of neuroblastoma in offspring. Am. J. Epidemiol. 154(2), 106-114 (2001).
10. Knudson AGJ, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am. J. Hum. Genet. 24, 514 (1972).
11. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad Sci. USA 68, 8820 (1971).
12. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma: Case reports, literature review and etiologic considerations. Cancer 57, 1887 (1986).
13. Maris JM, Kyemba SM, Rebbeck TR et al. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res, 56, 3421-3425 (1996).
14. Maris JM, Kyemba SM, Rebbeck TR et al. Molecular Genetic Analysis of familial neuroblastoma. Eur. J. Cancer 33, 1923-1928 (1997).
15. Chompret A, de Vatherie F, Brugieres L et al. Excess of cancers in relatives of patients with neuroblastoma. Med Pediatr Oncol. 31, 211A (1998).
16. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and Genetics of human neuroblastoma. J. Pediatr. Hematol. Oncol. 19, 93 (1997). Good review of the genetics of neuroblastoma.
17. The I, Murthy AE, Hannigan GE et al. Neurofibromatosis Type 1 gene mutations in neuroblastoma. Nature Genet 3, 62-66 (1993).
18. Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J. Clin. Oncol. 20(5), 1209-1214 (2002).
19. Bergerone C, Tofese T, Herble R. European experience with screening for neuroblastoma before the age of 12 months. Med Pediatr Oncol. 31, 442-449 (1998).
20. Woods WG, Tuchman M, Robison LL et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 348, 1682-1687 (1996).
21. Woods WG, Tuchman M, Robison LL. Screening for neuroblastoma in infants does not reduce population based mortality. Proc. Am J. Clin. Oncol. 19, 581a (2000) (Abstract 2285).
22. Kaplan SJ, Holbrook CT, McDaniel HG, Buntain WL, Crist WM. Vasoactive intestinal peptide secreting tumors of childhood. Am J. Dis. Child 134, 21-24 (1980).
23. El Shafie M, Samuel D, Klippel CH, Robinson MG, Cullen BJ. Intractable diarrhea in children with VIP-secreting ganglioneuroblastoma. J. Pediatr Surg. 18, 34-36(1983).
24. Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opsomyoclonus and neuroblastoma. Cancer 37, 846-852 (1976).
25. Pranzatelli MR. The neurobiology of the opsodonus-myodonus syndrome. Clin. Neuropharmacol. 15, 186-228(1992).
26. Kinast M, Levin HS, Rothner AD, Erenberg G, Wacksman J, Judge J. Cerebellar ataxia, opsoclonus and occult neural crest tumor. Abdominal computerized tomography in diagnosis. Am. J. Dis. Child 134, 1057-1059 (1980).
27. Black J, Williams DI. Natural history of adrenal hemorrhage in the newborn. Arch. Dis. Child 48, 183-190 (1973).
28. Murthy TVM, Irving IM, Lister J. Massive adrenal hemorrhage in neonatal neuroblastoma J. Pediatr Surg. 13, 31-34 (1978).
29. Triche TJ, Askin FB, Kissane JM. Neuroblastoma, Ewing's sarcoma and the differential diagnosis of small-, round-, blue-cell tumors. In: Pathology of neoplasia in children and adolescents. Finegold M (Ed.) Saunders WB Comp., PA, USA 145-195 (1986). Good paper addressing small, round blue cell tumors.
30. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. The International Neuroblastoma Pathology Classification. Cancer 86(2), 364-72 (1999). Excellent reference for tumor classification.
31. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. Prog. Clin. Biol. Res. 385, 363-369 (1994).
32. Nitschke R, Smith El, Shochat S et al. Localized neuroblastoma treated by surgery - a Pediatric Oncology Group study. J. Clin. Oncol. 6,1271-1279 (1988).
33. Matthay KK, Perez C, Seeger RC et al. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J. Clin. Oncol. 16, 1256-1264 (1998).
34. Schmidt ML, Lukens JN, Seeger RC et al. Biologic factors determine prognosis in infants with Stage 4 neuroblastoma: A prospective Children's Cancer Group study. J. Clin. Oncol. 18, 1260-1268 (2000).
35. Perez CA, Matthay KK, Atkinson JB et al. Biologic variables in the outcome of Stage I and II neuroblastom treatemd with surgery as primary therapy: a Children's Cancer Group study. J. Clin. Oncol. 18, 18-26 (2000).
36. Castleberry RP, Kun LE, Shuster JJ et al. Radiotherapy improves the outlook for children older than one year with POG stage C neuroblastoma. J. Clin. Oncol. 9, 789-795 (1991).
37. Nitschke R, El Smith El, G Altshuler G et al. Treatment of grossly unresectable localized neuroblastoma. A Pediatric Oncology Group study. J. Clin. Oncol. 9, 1181-1188 (1991).
38. Bowman LC, Castleberry RP, Cantor A et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J. Natl Cancer Inst. 89, 373-380 (1997).
39. Daubenton JD, Fisher RM, Karabus CD, Mann MD. The relationship between prognosis and scintigraphic evidence of bone metastasis in neuroblatsoma. Cancer 59, 1586-1589 (1987).
40. Heisel MA, Miller JH, Reid BS, Siegel SE. Radionuclide bone scan in neuroblastoma. Pediatrics 71, 206-209 (1983).
41. Podrasky AE, Stark DD, Hattner RS, Gooding CA, Moss AA. Radionuclide bone scanning in neuroblastoma: skeletal metastases and primary tumor localization of 99mTc-MDP. Am. J. Roentgenol 141, 469-472 (1983).
42. White SJ, Stuck KJ, Blane CE, Silver TM. Sonography of neuroblastoma. Am. J. Roentgenol. 141, 465-468 (1983).
43. Couanet D, Hartmann O, Piekarski JD, Vanel D, Masselot J. The use of computed tomography in the staging of neuroblastoma in childhood. Arch. Fran. Pediatr 38, 315-318 (1981).
44. Golding SJ, McElwain TJ, Husband JE. The role of computed tomography in the management of children with advanced neuroblastoma. Br. J. Radiol. 57, 661-666 (1984).
45. Fletcher BD, Kopiwoda SY, Strandjord SE, Nelson AD, Pickering SP. Abdominal neuroblastoma: magnetic resonance imaging and tissue characterization. Radiology 155, 699-703 (1985).
46. Smith FW, Cherryman GR, Redpath TW, Crosher G. The nuclear magnetic resonance appearances of neuroblastoma. Pediatr. Radiol. 15, 329-332 (1985).
47. Brodeur GM, Seeger RC, Barrett A et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J. Clin. Oncol. 6, 1874-1881 (1988).
48. Brodeur GM, Pritchard J, Berthold F et al. Revisions in the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. 11, 1466-1477 (1993).
49. Bostrom B, Nesbit ME, Brunning RD. The value of bone marrow trephine biopsy in the diagnosis of metastatic neuroblastoma. Am. J. Pediatr. Hematol Oncol 7, 303-305 (1985).
50. Franklin IM, Pritchard J. Detection of bone marrow invasion by neuroblastoma is improved by sampling at two sites with both aspirates and trephine biopsies. J. Clin. Pathol. 36, 1215-1218 (1983).
51. Cheung NK, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow. When is routine marrow histology insensitive? J. Clin. Oncol. 15, 2807-2817 (1997).
52. Otten J, Maurus R. Clinical trial of peptichemio in solid tumors of childhood. Cancer Treat. Rep. 62, 1015-1059 (1978).
53. Carli M, Green AA, Hayes FA et al. Therapeutic efficacy of single drugs for childhood neuroblastoma: a review. In: Pediatric Oncology. Raybaud C, Clement R, Lebeuil G (Ed.). Excerpta. Medica, Amsterdam, The Netherlands 141-150 (1982).
54. De Bemardi B, Comelli A, Mori PG, Massimo L Peptichemio in disseminated neuroblastoma. Proc. Am. Assoc. Cancer Res. 17, 143 (1976).
55. Starling KA, Sutow WW, Donaldson MH, Land VJ, Lane DM. Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone. Cancer Chemother. Rep. 58, 683-688 (1974).
56. Thurman WG, Fernbach DJ, Sullivan MP et al. Cyclophosphamide therapy in childhood neuroblastoma. N. Engl. J. Med. 270, 1336-1340 (1964).
57. Sweeney MJ, Turtle AH, Etteldorf JN et al. Cyclophosphamide in the treatment of common neoplastic diseases of childhood. J. Pediatr 61, 702-708 (1962).
58. Pinkel D. Cyclophosphamide in children with cancer. Cancer 15, 42-49 (1962).
59. Kontras SB, Newton WA. Cyclophosphamide (Cytoxan) therapy of childhood neuroblastoma: preliminary report. Cancer Chemother. Rep. 12, 39-50 (1961).
60. Green AA, Hayes FA, Pratt CB et al. Phase II evaluation of cisplatin in children with neuroblastoma and other malignant solid tumors. In: Cisplatin: current status and new developments. Prestyko AW, Crooke ST, Carter SK (Eds). Academic Press, NY, USA 477-484 (1980).
61. Nitschke R, Starling K, Land V et al. Cisplatinum (CDDP) in childhood malignancies. Proc. Am. Soc. Clin. Oncol. 17, 310 (1976).
62. Kamalakar P, Freeman AI, Higby DJ, Wallace HJ Jr, Sinks LF. Clinical response and toxicity with cisdichlorodiammineplatinum (II) in children. Cancer Treat. Rep. 61, 835-839 (1977).
63. Evans AE, Baehner RL, Chard RL Jr, Leikin SL, Pang EM, Pierce M. Comparison of daunorubicin (NSC-83142) with Adriamycin (NSC 123127) in the treatment of late stage childhood solid tumors. Cancer Chemother. Rep. 58, 671-676 (1974).
64. Pratt CB, Shanks EC. Doxombicin in treatment of malignant solid tumors in children. Am. J. Dis. Child 127, 534-537 (1974).
65. Ragab AH, Sutow WW, Komp DM, Starling KA, Lyon GM Jr, George S. Adriamycin in the treatment of childhood solid tumors. Cancer 36, 1567-1571 (1975).
66. Tan C, Cubanas E, Wollner N et al. Adriamycin: an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32, 9-17 (1973).
67. Wang JJ, Cortes E, Sinks LF, Holland JF. Therapeutic effect and toxicity of Adriamycin in patients with neoplastic disease. Cancer 28, 837-843 (1971).
68. Bleyer WA, Krivit W, Chard RL, Hammond D. Phase II study of VM-26 in acute leukemia, neuroblastoma and other refractory childhood malignancies; a report from the Children's Cancer Study Group. Cancer Treat. Rep. 63, 977-981 (1979).
69. Rivera G, Green A, Hayes A, Avery T, Pratt C. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma. Cancer Treat. Rep. 61, 1243-1248 (1977).
70. Sutow WW, Berry DH, Haddy TB, Sullivan MP, Watkins WL, Windmiller J. Vincristine sulfate in the treatment of neuroblastoma in children. Am. J. Dis. Child 3, 75-78 (1966).
71. Selawry OS, Holland JF, Wolman IJ. Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother. Rep. 52, 497-500 (1968).
72. Sullivan MP, Nora AH, Kulapongs P, Lane DM, Windmiller J, Thurman WG. Evaluation of vincristine sulfate and cyclophosphamide chemotherapy for metastatic neuroblastoma. Pediatrics 44, 685-694 (1969).
73. Komp DM, Land VJ, Nitschke R, Cangir A, Dyment P. 5-(3,3-Bis(2 chlorethyl)-1-triazinoimidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy. Cancer Chemother. Rep. 59, 371-376 (1975).
74. Finklestein JZ, Albo V, Ertel I, Hammond D. 5-(3, 3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of solid tumors in children. Cancer Chemother Rep 59, 351-357 (1975).
75. Samuels LD, Newton WA, Heyn R. Daunorubicin therapy in advanced neuroblastoma. Cancer 27, 831-834 (1971).
76. Sutow WV, Fembach DJ, Thurman WG et al. Dauorubicin (NSC-82151) in the treatment of metastatic neuroblastoma. Cancer Chemother. Rep. 54, 283-289 (1970).
77. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 20, 333-353 (1967).
78. Lindsley K, LaQuaglia M, Kushner BH et al. Hyperfractionated radiotherapy for consolidation of advanced stage neuroblastoma following intensive chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 27, 132 (1993).
79. Cheung NK, Kushner BH, LaQuaglia M et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med. Pediatr. Oncol. 36(1), 227-30 (2001).
80. Cheung NK, Yu A. Immunotherapy of Neuroblastoma. In: Neuroblastoma. Brodeur GM, Sawada T, Tsuchida Y, Voute P (Eds). PA, USA (1999).
81. Matthay KK, Villablanca JG, Seeger RC et al. Treatment on high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-isotretinoin. N. Engl. J. Med. 341: 1165-1173 (1999).
82. Reynolds CP, Villablanca JG, Stram DO et al. 13-isotrednoin after intensive consolidation therapy for neuroblastoma improves event free survival: a randomized children's cancer group (CCG) study. Proc. Ann. Soc. Clin. Oncol. 17, 2a (1998).
83. Larson SM, Sgouros G, Cheung NK. Radiolabeled antibodies: general issues. Encycl. Cancer 3, 1420-1431 (1997).
84. Cheung NKV. Biologic and molecular approaches to diagnosis and treatment In: Principles and Practice of Pediatric Oncology, Section 1 (3rd Edition) Lippincott, Williams and Wilkens, PA, USA 323-342 (1997). Excellent review of new treatment approaches.
85. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J. Clin. Pathol. 54(12), 897-910 (2001). Excellent overview of neuroblastoma tumor genetics and description of techniques used for diagnosis in neuroblastoma.
86. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol. Biol. Cell. 12(5), 1315-1328 (2001).
87. Iwanaga Y, Jeang KT. Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. Cancer Res. 62(9), 2618-2624 (2002).
88. Hernando E, Orlow I, Liberal V, Nohales G, Benezra R, Cordon-Cardo C. Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int. J. Cancer 95(4), 223-227 (2001).
89. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 311(4), 231-235 (1984). Correlation between DNA ploidy and prognosis in neuroblastoma tumors.
90. Muraji T, Okamoto E, Fujimoto J, Suita S, Nakagawara A. Combined determination of N-myc oncogene amplification and DNA ploidy in neuroblastoma. Complementary prognostic indicators. Cancer 72(9), 2763-2768 (1993).
91. Eckschlager T, Pilat D, Kodet R et al. DNA ploidy in neuroblastoma. Neoplasma 43 (1), 23-26 (1996).
92. Huddart SN, Muir KR, Parkes SE et al. Retrospective study of prognostic value of DNA ploidy and proliferative activity in neuroblastoma. J. Clin. Pathol. 46(12), 1101-1104 (1993).
93. Look AT, Hayes FA, Shuster JJ et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 9(4), 581-591 (1991). Good report on different genetic features with influence on outcome.
94. Cohn SL, Rademaker AW, Salwen HR et al. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am. J. Pathol. 136 (5), 1043-1052 (1990).
95. Gerstner AO, Machlitt J, Laffers W, Tarnok A, Bootz E Analysis of minimal sample volumes from head and neck cancer by laser scanning cytometry. Onkologie 25 (1), 40-46 (2002).
96. Wojcik EM, Saraga SA, Jin JK, Hendricks JB. Application of laser scanning cytometry for evaluation of DNA ploidy in routine cytologic specimens. Diagn. Cytopathol. 24(3), 200-205 (2001).
97. Tsukazaki Y, Numa Y, Zhao S, Kawamoto K. Analysis of DNA-ploidy using laser scanning cytometer in brain tumors and its clinical application. Hum. Cell 13(4), 221-228 (2000).
98. Truong K, Vielh P, Guilly MN et al. Quantitative FISH analysis on interphase nuclei may improve diagnosis of DNA diploid breast cancers. Diagn. Cytopathol. 26(4), 213-216 (2002).
99. Tajiri T, Tanaka S, Suita S et al. Effectiveness of FISH method for analysis of biology in neuroblastoma. J. Jpn. Coll. Surg. 25, 835-840 (2000).
100. Stark B, Jeison M, Bar-Am I et al. Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping. Genes Chrom. Cancer 34, 313-324 (2002).
101. Dang CV, Resar LM, Emison E et al. Function of the c-Myc oncogenic: transcription factor. Exp. Cell. Res. 253, 63-77 (1999).
102. Wartiovaara K, Bamabe-Heider F, Miller FD, Kaplan DR. N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. J. Neurosci. 22, 815-824 (2002).
103. Rossler J, Schwab M, Havers W, Schweigerer L. Hypoxia promotes apoptosis of human neuroblastoma cell lines with enhanced N-myc expression. Biochem. Biophys. Res. Commun. 281, 272-276 (2001).
104. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogenewith rapid progression of neuroblastomas. N. Eng. J. Med. 313, 1111-1116 (1985). Describes the influence of MYCN on neuroblastoma tumors growth.
105. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet. Cytogenet. 41, 153-174 (1989).
106. Tajiri T, Suita S, Sera Y et al. Committee for Pediatric Solid Malignant Tumors in the Kyushu Area. Clinical and biologic characteristics for recurring neuroblastoma at mass screening cases in Japan. Cancer 92, 349-353 (2001).
107. Schwab M. Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin. Cancer Biol. 4, 13-18 (1993).
108. Schwab M. Where pathology meets molecular biology: N-myc amplification in human neuroblastoma as a paradigm for the clinical use of an oncogene alteration. Verh Dtsch Ges Pathol. 78, 26-33 (1994). Good review about the biological influence of MYC Non neuroblastoma tumors.
109. Slavc I, Ellenbogen R, Jung WH et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res. 50, 1459-1463 (1990).
110. Matthay KK. MYCN expression in neuroblastoma: a mixed message? J. Clin. Oncol. 18, 3591-3594 (2000).
111. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. J. Pediatr. Hematol. Oncol. 19, 93-101 (1997).
112. Brodeur GM. Neuroblastoma-clinical applications of molecular parameters. Brain Pathol. 1, 47-54 (1990).
113. George RE, Kenyon RM, McGuckin AG, Malcolm AJ, Pearson AD, Lunec J. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc inneuroblastoma. United Kingdom Children's Cancer Study Group. Oncogene 12, 1583-1587 (1996). Report of some of the genes coamplified with MYCN in neuroblastic tumors.
114. Schwab M, Varmus HE, Bishop JM. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature 316, 160-162 (1985). Original description of the MYCN-derived oncogenesis.
115. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995 (1997).
116. Barroca H, Carvalho JL, da Costa MJ, Cirnes L, Seruca R, Schmitt FC. Detection of N-myc amplification in neuroblastomas using Southern blotting on fine needle aspirates. Acta Cytol. 45, 169-172 (2001).
117. Hiyama E, Hiyama K, Ohtsu K et al. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1. Med. Pediatr. Oncol. 36, 67-74 (2001).
118. Tajiri T, Shono K, Fujii Y et al. Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization. J. Pediatr. Surg. 34, 1615-1619 (1999).
119. Aldosari N, Bigner SH, Burger PC et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch. Pathol. Lab. Med. 126, 540-544 (2002).
120. Michiels EM, Weiss MM, Hoovers JM et al. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J. Pediatr. Hematol. Oncol. 24, 205-210 (2002).
121. Gilhuis HJ, Anderl KL, Boerman RH et al. Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin. Neurol. Neurosurg. 102, 203-209 (2000).
122. Hayashi Y, Kanda N, Inaba T et al. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 63, 126-132 (1989).
123. Ambros PF, Ambros IM, Kerbl R et al. Intratumoural heterogeneity of lp deletions and MYCN amplification in neuroblastomas. Med. Pediatr. Oncol. 36, 1-4 (2001).
124. Maris JM, Guo C, Blake D et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med. Pediatr. Oncol. 36, 32-36 (2001).
125. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur. J. Cancer 31, 505-510 (1995).
126. Weith A, Martinsson T, Cziepluch C et al. Neuroblastoma consensus deletion maps to lp36.1-2. Genes Chromo. Cancer 1, 159-166 (1989).
127. Hogarty MD, Maris JM, White PS, Guo C, Brodeur GM. Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Med. Pediatr. Oncol. 36, 52-55 (2001).
128. Ejeskar K, Sjoberg RM, Abel F, Kogner P, Ambros PF, Martinsson T. Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med. Pediatr. Oncol. 36, 61-66 (2001).
129. Mora J, Cheung NK, Kushner BH et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. Mol. Diagn. 2, 37-46 (2000).
130. Roberts T, Chemova O, Cowell JK, Molecular characterization of the 1p22 breakpoint region spanning the constitutional translocation breakpoint in a neuroblastoma patient with a t(1;10)(p22;q21). Cancer Genet. Cytogenet. 100, 10-20 (1998).
131. Spitz R, Hero B, Westermann F, Ernestus K, Schwab M, Berthold E Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromo. Cancer 34, 299-305 (2002).
132. Kaghad M, Bonnet H, Yang A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819 (1997).
133. Ichimiya, S, Nimura Y, Kageyama H et al. Genetic analysis ofp73 localized at chromosome 1p36.3 in primary neuroblastomas. Med. Pediatr. Oncol. 36, 42-44 (2001).
134. Barrois M, Eychenne MK, Terrier-Lacombe MJ et al. Genomic and allelic expression status of the p73 gene in human neuroblastoma. Med. Pediatr. Oncol. 36, 45-47 (2001).
135. Roberts T, Chemova O, Cowell JK. NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma. Hum. Mol. Genet. 7, 1169-1178 (1998).
136. Yang HW, Chen YZ, Piao HY, Takita J, Soeda E, Hayashi Y. DNA fragmentation factor 45 (DFF45) gene at 1p36.2 is homozygously deleted and encodes variant transcripts in neuroblastoma cell line. Neoplasia 3, 165-169 (2001).
137. Yu Y, Xu F, Peng H et al. NOEY2 (ARH1), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl Acad. Sci. USA 96, 214-219 (1999).
138. Mora J, Cheung NK, Gerald WL. Genetic heterogeneity and clonal evolution in neuroblastoma. Br. J. Cancer 85, 182-189 (2001).
139. Nigro JM, Takahashi MA, Ginzinger DG et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am. J. Pathol. 158, 1253-1262 (2001).
140. Brinkschmidt C, Christiansen H, Terpe HJ et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med. Pediatr. Oncol. 36, 11-13 (2001).
141. Squire JA, Thorner P, Marrano P et al. Identification of MYCN copy number heterogeneity by direct FISH analysis of neuroblastoma preparations. Mol. Diagn. 1, 281-289 (1996).
142. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med. Pediatr. Oncol. 24, 215-221 (1995).
143. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am. J. Hum. Genet. 55, 334-340 (1994).
144. Caron H, van Sluis P, van Roy N et al. Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am. J. Hum. Genet. 55, 341-347 (1994).
145. Lastowska M, Cotterill S, Bown N et al. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromo. Cancer 34, 428-436 (2002).
146. Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340, 1954-1961 (1999).
147. Janoueix-Lerosey I, Penther D, Thioux M et al. Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromo. Cancer 28, 276-284 (2000).
148. Tajiri T, Shono K, Tanaka S, Suita S. Evaluation of genetic heterogeneity in neuroblastoma. Surgery 131, S283-287 (2002).
149. Tajiri T, Tanaka S, Shono K et al. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett. 166, 89-94 (2001).
150. Brinkschmidt C, Christiansen H, Terpe HJ et al. Comparative genomic hybridization (CGH) analysis of neuroblastomas - an important methodological approach in paediatric tumour pathology. J. Pathol. 181, 394-400 (1997). Good description of the technique and its application in neuroblastic tumors.
151. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 41, 4678-4686 (1981). Good overview of different genetic characteristics of neuroblastic samples.
152. Vandesompele J, Speleman F, Van Roy N et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med. Pediatr. Oncol. 36, 5-10 (2001).
153. Mora J, Cheung NK, Oplanich S, Chen L, Gerald WL. Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res. 62, 1761-1767 (2002).
154. Mora J, Cheung NK, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin. Cancer Res. 7, 1358-1361 (2001).
155. MacPhee DG. Epigenetics and epimutagens: some new perspectives on cancer, germ line effects and endocrine disrupters. Muta. Res. 400, 369-379 (1998).
156. Holliday R. DNA methylation in eukaryotes: 20 years on. In: Epigenetic Mechanisms of Gene Regulation. Russo VEA Mardenssen RA, Riggs AD (Eds). Cold Spring Harbor Press, NY, USA, 5-27 (1996).
157. Matsunaga T, Shirasawa H, Enomoto H et al. Neuronal src and trk-a protooncogene expression in neuroblastomas and patient prognosis. Int. J. Cancer 79, 226-31 (1998).
158. Horibe K, Fukuda M, Miyajima Y et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med. Pediatr. Oncol. 36, 203-204 (2001).
159. Orlando C, Gelmini S. Telomerase in endocrine and endocrine-dependent tumors. J. Steroid Biochem. Mol. Biol. 78, 201-214 (2001).
160. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. 1, 249-255 (1995).
161. Reynolds CP, Zuo JJ, Kim NW et al. Telomerase expression in primary neuroblastomas. Eur. J. Cancer. 33, 1929-1931 (1997).
162. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 169(2), 107-114 (2001).
163. Chao MV, Bothwell MA, Ross AH et al. Gene transfer and molecular cloning of the human NGF receptor. Science 232, 518-521 (1986).
164. Hoehner JC, Olsen L, Sandstedt B, Kaplan DR, Pahlman S. Association of neurotrophinreceptor expression and differentiation in human neuroblastoma. Am. J. Pathol. 147, 102-113(1995).
165. Yamashiro DJ, Liu XG, Lee CP et al. Expression and function of Trk-C in favorablehuman neuroblastomas. Eur. J. Cancer 33, 2054-2057 (1997).
166. Brodeur GM, Nakagawara A, Yamashiro DJ et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J. Neurooncol. 31(1-2), 49-55 (1997).
167. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell Biol. 14, 759-767 (1994).
168. Kaya G, Laurini R, Chaubert P, Gross N. Expression of CD44 and its isoforms in the fetal neuroblasts. Appl. Immunohistochem. Mol. Morphol. 9, 180-184 (2001).
169. Gross N, Balmas Bourloud K, Brognara CB. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells. Exp. Cell Res. 260, 396-403 (2000).
170. Kramer K, Cheung NK, Gerald WL et al. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur. J. Cancer. 33, 2098-2100 (1997).
171. Gross N, Balmas K, Beretta Brognara C. Role of CD44H carbohydrate structure in neuroblastoma adhesive properties. Med. Pediatr. Oncol. 36, 139-141 (2001).
172. Krajewski S, Chatten J, Hanada M, Reed JC. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-myc protein. Lab. Invest. 72, 42-54 (1995).
173. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J. Mol. Med. 79, 428-436 (2001).
174. Kitanaka C, Kato K, Ijiri R et al. Increased Ras expression and caspase-independent neuroblastomacell death: possible mechanism of spontaneous neuroblastoma regression. J. Natl Cancer Inst. 94, 358-368 (2002).
175. Ungar DR, Hailat N, Strahler JR et al. Hsp27 expression in neuroblastoma: correlation with disease stage. J. Natl Cancer Inst. 86, 780-784 (1994).
176. Ikeda H, Nakamura Y, Hiwasa T et al. Interleukin-1 beta converting enzyme (ICE) is preferentially expressed in neuroblastomas with favourable prognosis. Eur. J. Cancer 33, 2081-2083 (1997).
177. Kogner P, Borgstrom P, Bjellerup P et al. Somatostatin in neuroblastoma and ganglioneuroma. Eur. J. Cancer 33, 2084-2089 (1997).
178. Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM, Ikegaki N. Association among EPHB2, TrkA and MYCN expression in low-stage neuroblastomas. Med. Pediatr. Oncol. 36, 80-82 (2001).
179. Castleberry RP Neuroblastoma. Eur. J. Cancer 33, 1430-1437 (1997). Good review on neuroblastoma.
180. Takeda O, Handa M, Uehara T et al. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas. Br. J. Cancer 74, 1620-1626 (1996).
181. Misawa A, Hosoi H, Arimoto A et al. N-myc induction stimulated by insulin-like growth Factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res. 60, 64-69 (2000).
182. George RE, Kenyon R, McGuckin AG et al. Analysis of candidate gene coamplification with MYCN in neuroblastoma. Eur. J. Cancer 33, 2037-2042 (1997).
183. Chan HS, Gallie BL, DeBoer G et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin. Cancer Res. 3, 1699-1706 (1997).
184. Iwanaka T, Arai M, Ito M et al. Surgical treatment for abdominal neuroblastoma in the laparoscopic era. Surg. Endosc. 15(7), 751-754 (2001).
185. Shalhav AL, Chan SW, Bercowsky E, Elbahnassy AM, McDougall EM, Clayman RV. Laparoscopic exploration in the management of retroperitoneal masses. J. Soc. Laparoendoscopic Surg. 3, 209-214 (1999).
186. Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J. Mol. Diagn. 4, 30-36 (2002).
187. Sklair-Levy M, Lebensart PD, Applbaum YH et al. Percutaneous image-guided needle biopsy in children-summary of our experience with 57 children. Pediatr. Radiol. 31, 732-736 (2001).
188. Mitelman F. ISCN (1995): an international system for human cytogenetic nomenclature. Karger S. Basel, Switzerland (1995). Description of the different regions and karyotypic features of all human chromosomes for universal nomenclature.
189. Biesecker L, du Manoir S, Ried T. Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum. Genet. 101, 255-262 (1997).
190. Cohen N, Betts DR, Trakhtenbrot L et al. Detection of unidentified chromosome abnormalities in human neuroblastoma by spectral karyotyping (SKY). Genes Chromo. Cancer. 31, 201-208 (2001).
191. Schrock E, Veldman T, Padilla-Nash H et al. Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum. Genet. 101, 255-262 (1997).
192. Veldman T, Vignon C, Schrock E, Rowley JD, Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nature Genet. 15, 406-410 (1997).
193. Mora J, Cheung NK, Juan G et al. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res. 61, 6892-6898 (2001).
194. Dotsch J, Repp R, Rascher W, Christiansen H. Diagnostic and scientific applications of TaqMan real-time PCR in neuroblastomas. Expert Rev. Mol. Diagn. 1, 233-238 (2001).
195. Nisen PD, Waber PG, Rich MA et al. N-myc oncogene RNA expression in neuroblastoma. J. Natl Cancer Inst. 80, 1633-1637 (1988).
196. Cohn SL, London WB, Huang D et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol. 18, 3604-3613 (2000).
197. Johnstone A and Thorpe R (Eds.). Immunochemistry in practice (2nd Ed.) MA, USA (1987).
198. Johnstone A. Immunological techniques. Curr. Opin. Immunol. 1, 927 (1989). Guide to immunological procedures in pathologic diagnosis.
199. Packeisen J, Buerger H, Krech R, Boecker W. Tissue microarrays: a new approach for quality control in immunohistochemistry, J. Clin. Pathol. 55, 613-615 (2002).
200. Kaneko Y, Kanda N, Maseki N et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res. 47, 311-318 (1987).
201. Taylor SR, Roederer M, Murphy RF et al. Flow cytometric DNA analysis of adenocortical tumors in children. Cancer. 59, 2059-2063 (1987).
202. Boerner S, Squire J, Thomer P, McKenna G, Zielenska M. Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction. Pediatr. Pathol. 14, 823-832 (1994).
203. Sartelet H, Grossi L, Pasquier D et al. Detection of N-myc amplification by FISH in immature areas of fixed neuroblastomas: more efficient than Southern blot/PCR. J. Pathol. 198, 83-91(2002).
204. Gallego S, Reventos J, Sanchez de Toledo J, Munell F. Differential polymerase chain reaction with serial dilutions for quantification of MYCN gene amplification in neuroblastoma. AntiCancer Res. 18, 1211-1215 (1998).
205. Gilbert E Feder M, Balaban G et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 44(11), 5444-5449 (1984).
206. Taylor CPF, McGuckin AG, Bown NP et al. Rapid detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridization on tumor imprints and bone marrow smears. Br. J. Cancer 69, 445-451 (1994). Description of FISH for characterization of neuroblastic tumors.
207. Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA. Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia 3, 62-69 (2001).